Chargement en cours...
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and c...
Enregistré dans:
| Publié dans: | Pharmaceuticals (Basel) |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8151172/ https://ncbi.nlm.nih.gov/pubmed/34064559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14050450 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|